ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by Haidukon Aug 12, 2021 1:44pm

228 Views

Post# 33694875

MD&A – June 30, 2021

Interesting information in the last MD&A (Aug 12, 2021) about the “Significant Projects” – PMN310, TDP-43 (ALS), Alpha-synuclein (Parkinson’s disease) and Alzheimer’s Vaccine Program -, the required capital for each of those (within 12 months and on the long term), as well as on the “Company’s current business objectives for the next 12 months and the milestones (including estimated costs and timing) associated with attaining those objectives”.

Worth reading.

https://www.sedar.com/search/search_form_pc_en.htm

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments